{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:08:21Z","timestamp":1790125701689,"version":"4.0.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"DOI":"10.1186\/s10194-025-02160-7","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T13:01:51Z","timestamp":1760706111000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["CGRP-targeted therapy fulfilling the treatment gap in medication-underuse setting: a retrospective cohort study at a tertiary headache center in Thailand, a lower-middle-income country"],"prefix":"10.1186","volume":"26","author":[{"given":"Sirawit","family":"Roongrojwittayakul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakit","family":"Anukoolwittaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akarin","family":"Hiransuthikul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanakit","family":"Pongpitakmetha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sekh","family":"Thanprasertsuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanakorn","family":"Rattanawong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"issue":"4","key":"2160_CR1","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/S1474-4422(24)00038-3","volume":"23","author":"Global","year":"2024","unstructured":"Global (2024) regional, and National burden of disorders affecting the nervous system, 1990\u20132021: a systematic analysis for the global burden of disease study 2021. Lancet Neurol 23(4):344\u2013381","journal-title":"Lancet Neurol"},{"issue":"9","key":"2160_CR2","doi-asserted-by":"publisher","first-page":"333102424126973","DOI":"10.1177\/03331024241269735","volume":"44","author":"F Puledda","year":"2024","unstructured":"Puledda F, Sacco S, Diener HC, Ashina M, Al-Khazali HM, Ashina S et al (2024) International headache society global practice recommendations for preventive Pharmacological treatment of migraine. Cephalalgia 44(9):3331024241269735","journal-title":"Cephalalgia"},{"issue":"10483","key":"2160_CR3","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/S0140-6736(25)00109-6","volume":"405","author":"J Versijpt","year":"2025","unstructured":"Versijpt J, Paemeleire K, Reuter U, MaassenVanDenBrink A (2025) Calcitonin gene-related peptide-targeted therapy in migraine: current role and future perspectives. Lancet 405(10483):1014\u20131026","journal-title":"Lancet"},{"issue":"1","key":"2160_CR4","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s10194-024-01859-3","volume":"25","author":"P Anukoolwittaya","year":"2024","unstructured":"Anukoolwittaya P, Hiransuthikul A, Pongpitakmetha T, Thanprasertsuk S, Rattanawong W (2024) Filling the data gap on CGRP mAb therapy in low- to middle-income countries in Southeast asia: insights from a real-world study in Thailand. J Headache Pain 25(1):150","journal-title":"J Headache Pain"},{"issue":"4","key":"2160_CR5","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/head.12055","volume":"53","author":"AM Blumenfeld","year":"2013","unstructured":"Blumenfeld AM, Bloudek LM, Becker WJ, Buse DC, Varon SF, Maglinte GA et al (2013) Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache 53(4):644\u2013655","journal-title":"Headache"},{"issue":"4","key":"2160_CR6","doi-asserted-by":"publisher","first-page":"333102424124565","DOI":"10.1177\/03331024241245658","volume":"44","author":"W Rattanawong","year":"2024","unstructured":"Rattanawong W, Rapoport A, Srikiatkhachorn A (2024) Medication underuse headache. Cephalalgia 44(4):3331024241245658","journal-title":"Cephalalgia"},{"key":"2160_CR7","doi-asserted-by":"publisher","first-page":"100427","DOI":"10.1016\/j.ensci.2022.100427","volume":"29","author":"D Mortel","year":"2022","unstructured":"Mortel D, Kawatu N, Steiner TJ, Saylor D (2022) Barriers to headache care in low- and middle-income countries. eNeurologicalSci 29:100427","journal-title":"eNeurologicalSci"},{"key":"2160_CR8","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia (2018) ;38(1):1-211","DOI":"10.1177\/0333102417738202"},{"issue":"9","key":"2160_CR9","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1177\/0333102419835465","volume":"39","author":"M Bonafede","year":"2019","unstructured":"Bonafede M, Wilson K, Xue F (2019) Long-term treatment patterns of prophylactic and acute migraine medications and incidence of opioid-related adverse events in patients with migraine. Cephalalgia 39(9):1086\u20131098","journal-title":"Cephalalgia"},{"issue":"11","key":"2160_CR10","doi-asserted-by":"publisher","first-page":"e038972","DOI":"10.1136\/bmjopen-2020-038972","volume":"10","author":"V Orlando","year":"2020","unstructured":"Orlando V, Mucherino S, Monetti VM, Trama U, Menditto E (2020) Treatment patterns and medication adherence among newly diagnosed patients with migraine: a drug utilisation study. BMJ Open 10(11):e038972","journal-title":"BMJ Open"},{"key":"2160_CR11","doi-asserted-by":"publisher","first-page":"402","DOI":"10.18433\/jpps33158","volume":"25","author":"A Ojo","year":"2023","unstructured":"Ojo A, Zhang S, Bleibdrey N, Zimskind D, Keshvani N, Chalmers R (2023) Persistence and switching patterns of migraine prophylactic medications in canada: A retrospective claims analysis comparing adherence and evaluating the economic burden of illness. J Pharm Pharm Sci 25:402\u2013417","journal-title":"J Pharm Pharm Sci"},{"issue":"5","key":"2160_CR12","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/0333102416678382","volume":"37","author":"Z Hepp","year":"2017","unstructured":"Hepp Z, Dodick DW, Varon SF, Chia J, Matthew N, Gillard P et al (2017) Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis. Cephalalgia 37(5):470\u2013485","journal-title":"Cephalalgia"},{"issue":"5","key":"2160_CR13","doi-asserted-by":"publisher","first-page":"e0153380","DOI":"10.1371\/journal.pone.0153380","volume":"11","author":"R Meister","year":"2016","unstructured":"Meister R, von Wolff A, Mohr H, H\u00e4rter M, Nestoriuc Y, H\u00f6lzel L et al (2016) Comparative safety of Pharmacologic treatments for persistent depressive disorder: A systematic review and network Meta-Analysis. PLoS ONE 11(5):e0153380","journal-title":"PLoS ONE"},{"key":"2160_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s43856-021-00046-8","volume":"1","author":"AI Campos","year":"2021","unstructured":"Campos AI, Mulcahy A, Thorp JG, Wray NR, Byrne EM, Lind PA et al (2021) Understanding genetic risk factors for common side effects of antidepressant medications. Commun Med (Lond) 1:45","journal-title":"Commun Med (Lond)"},{"key":"2160_CR15","doi-asserted-by":"publisher","unstructured":"Kariis HM, S\u00e4rg D, Krebs K, J\u00f5eloo M, K\u00f5iv K, Sirts K et al (2025). Genetic influences on antidepressant side effects: a CYP2C19 gene variation and polygenic risk study in the Estonian biobank. Eur J Hum Genet. Advance online publication. https:\/\/doi.org\/10.1038\/s41431-025-01894-x.","DOI":"10.1038\/s41431-025-01894-x"},{"key":"2160_CR16","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/TACG.S463965","volume":"17","author":"V Nakhonsri","year":"2024","unstructured":"Nakhonsri V, John S, Panumasmontol H, Jantorn M, Chanthot P, Hanpramukkun N et al (2024) The diversity of CYP2C19 polymorphisms in the Thai population: implications for precision medicine. Appl Clin Genet 17:95\u2013105","journal-title":"Appl Clin Genet"},{"issue":"1","key":"2160_CR17","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1159\/000543331","volume":"15","author":"S Kittipanprayoon","year":"2025","unstructured":"Kittipanprayoon S, Vorasayan P, Chutinet A, Chariyavilaskul P, Suwanwela NC (2025) The prevalence of CYP2C19 polymorphism in patients with symptomatic intracranial atherosclerosis. Cerebrovasc Dis Extra 15(1):68\u201372","journal-title":"Cerebrovasc Dis Extra"},{"key":"2160_CR18","first-page":"85","volume":"6","author":"C Sukasem","year":"2013","unstructured":"Sukasem C, Tunthong R, Chamnanphon M, Santon S, Jantararoungtong T, Koomdee N et al (2013) CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors. Pharmgenomics Pers Med 6:85\u201391","journal-title":"Pharmgenomics Pers Med"},{"issue":"1","key":"2160_CR19","doi-asserted-by":"publisher","first-page":"18969","DOI":"10.1038\/s41598-020-76085-3","volume":"10","author":"J Mauleekoonphairoj","year":"2020","unstructured":"Mauleekoonphairoj J, Chamnanphon M, Khongphatthanayothin A, Sutjaporn B, Wandee P, Poovorawan Y et al (2020) Phenotype prediction and characterization of 25 pharmacogenes in Thais from whole genome sequencing for clinical implementation. Sci Rep 10(1):18969","journal-title":"Sci Rep"},{"issue":"1","key":"2160_CR20","doi-asserted-by":"publisher","first-page":"12343","DOI":"10.1038\/s41598-021-90969-y","volume":"11","author":"R Sukprasong","year":"2021","unstructured":"Sukprasong R, Chuwongwattana S, Koomdee N, Jantararoungtong T, Prommas S, Jinda P et al (2021) Allele frequencies of single nucleotide polymorphisms of clinically important drug-metabolizing enzymes CYP2C9, CYP2C19, and CYP3A4 in a Thai population. Sci Rep 11(1):12343","journal-title":"Sci Rep"},{"issue":"2","key":"2160_CR21","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1517\/14622416.3.2.229","volume":"3","author":"LD Bradford","year":"2002","unstructured":"Bradford LD (2002) CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3(2):229\u2013243","journal-title":"Pharmacogenomics"},{"issue":"1","key":"2160_CR22","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s10194-021-01335-2","volume":"22","author":"F Vandervorst","year":"2021","unstructured":"Vandervorst F, Van Deun L, Van Dycke A, Paemeleire K, Reuter U, Schoenen J et al (2021) CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. J Headache Pain 22(1):128","journal-title":"J Headache Pain"},{"issue":"1","key":"2160_CR23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s10194-025-01952-1","volume":"26","author":"W Rattanawong","year":"2025","unstructured":"Rattanawong W, Anukoolwittaya P, Hiransuthikul A, Pongpitakmetha T, Trisataya A, Thanprasertsuk S et al (2025) Medication underuse in real-life practice: the impact of galcanezumab towards achieving very low frequency episodic migraine in a Southeast Asian middle-income Nation. J Headache Pain 26(1):13","journal-title":"J Headache Pain"},{"issue":"1","key":"2160_CR24","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s10194-023-01594-1","volume":"24","author":"C Lampl","year":"2023","unstructured":"Lampl C, MaassenVanDenBrink A, Deligianni CI, Gil-Gouveia R, Jassal T, Sanchez-Del-Rio M et al (2023) The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis. J Headache Pain 24(1):56","journal-title":"J Headache Pain"},{"key":"2160_CR25","doi-asserted-by":"publisher","unstructured":"Ferreira A, Marques S, Lopes S, Mar\u00e9 R, Carneiro G, Lopes M et al. Preventive oral treatment in migraine: efficacy and dropout rates observed at a tertiary headache center. SN Compr Clin Med. 2022;5(1):38. https:\/\/doi.org\/10.1007\/s42399-022-01369-w.","DOI":"10.1007\/s42399-022-01369-w"},{"issue":"7","key":"2160_CR26","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1080\/13696998.2018.1457533","volume":"21","author":"RB Lipton","year":"2018","unstructured":"Lipton RB, Brennan A, Palmer S, Hatswell AJ, Porter JK, Sapra S et al (2018) Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective. J Med Econ 21(7):666\u2013675","journal-title":"J Med Econ"},{"issue":"10","key":"2160_CR27","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1111\/head.14612","volume":"63","author":"SJ Tepper","year":"2023","unstructured":"Tepper SJ, Schwedt TJ, Vo P, Thompson J, Joshi P, Abdrabboh A et al (2023) Healthcare costs and resource utilization in patients with migraine treated with erenumab: A retrospective, non-interventional study using claims data from the united States. Headache 63(10):1423\u20131436","journal-title":"Headache"},{"issue":"1","key":"2160_CR28","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s10194-023-01623-z","volume":"24","author":"J Pascual","year":"2023","unstructured":"Pascual J, Panni T, Dell\u2019Agnello G, Gonderten S, Novick D, Evers S (2023) Preventive treatment patterns and treatment satisfaction in migraine: results of the OVERCOME (EU) study. J Headache Pain 24(1):88","journal-title":"J Headache Pain"},{"issue":"1","key":"2160_CR29","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s10194-023-01666-2","volume":"24","author":"P Martelletti","year":"2023","unstructured":"Martelletti P, Leonardi M, Ashina M, Burstein R, Cho SJ, Charway-Felli A et al (2023) Rethinking headache as a global public health case model for reaching the SDG 3 HEALTH by 2030. J Headache Pain 24(1):140","journal-title":"J Headache Pain"},{"key":"2160_CR30","doi-asserted-by":"publisher","unstructured":"Wells-Gatnik WD, Martelletti P. Therapeutic barriers for headache management: issues facing the global North and global South in 2024. Expert Rev Neurother. 2025;10:1\u20133.\u00a0https:\/\/doi.org\/10.1080\/14737175.2025.2450647.","DOI":"10.1080\/14737175.2025.2450647"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02160-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-025-02160-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02160-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T13:02:00Z","timestamp":1760706120000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-025-02160-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2160"],"URL":"https:\/\/doi.org\/10.1186\/s10194-025-02160-7","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"assertion":[{"value":"16 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval was obtained from the ethics committee of Chulalongkorn University (IRB no. 1156\/2024). The procedures used in this study adhere to the tenets of the Declaration of Helsinki. The approval of retrieving retrospective data from electronic medical records (EMR) was made and informed consent was waived by IRBREC.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"SR and AH report no significant conflict of interest related to this topic. PA has received speaker and advisory board honoraria from BL HUA, DKSH, Lundbeck, Pfizer, and ZP Therapeutics. TP has received speaker honoraria from BL HUA, Daiichi Sankyo, Eisai, Lundbeck, Pfizer, Servier, and ZP Therapeutics. ST reports speaker and advisory board honoraria from BL HUA, DKSH, Lundbeck, Pfizer, Viatris, and ZP Therapeutics. WR declares receiving speaker and advisory board honoraria from BL HUA, DKSH, Lundbeck, Pfizer, Viatris, and ZP Therapeutics.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Conflict of interest"}}],"article-number":"224"}}